Breaking Finance News

A statement released earlier today by Commerzbank AG about MorphoSys (ETR:MOR) bumps the target price to 57.00EUR

Commerzbank AG bumped up the target of MorphoSys (ETR:MOR) to 57.00EUR stating a potential upside of 0.54%.

On 10/01/2016, Commerzbank AG released a statement on MorphoSys (ETR:MOR) bumped up the target price from 0.00EUR to 57.00EUR that suggested an upside of 0.54%.

Boasting a price of 37.04EUR, MorphoSys (ETR:MOR) traded 0.00% even on the day. With the last close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. MorphoSys has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Volume of trade was down over the average, with 0 shares of MOR changing hands under the typical 42,448

Performance Chart

MorphoSys (ETR:MOR)

With a total market value of 0 EUR, MorphoSys has with a one year low of 0.00EUR and a one year high of 0.00EUR .

More About MorphoSys (ETR:MOR)

MorphoSys AG (MorphoSys) develops and commercializes antibodies for therapeutic applications. The Company's operating segments include Proprietary Development and Partnered Discovery. The Company develops new treatments for patients suffering from serious diseases. The Company has a total of approximately 100 individual therapeutic antibody programs, among which are in Phase III trials. MorphoSys has developed various technologies, which offer direct access to fully human antibodies for the treatment of diseases. The Company's technologies include HuCAL, which is a collection of billions of fully human antibodies and a system for their optimization, and Ylanthia, which is an antibody library in Fab format based on the concept for generating specific and fully human antibodies. It is evaluating the clinical development of approximately three cancer programs, including MOR208, MOR202 and MOR209/ES414.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.